Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
NSCLC Stage IV · ALK Fusion Protein Expression
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Johns Hopkins University, Baltimore, Maryland, United States
Contact: Principal Investigator (Vincent Lam, MD)
Study leads
Vincent Lam, MD
Principal Investigator
Johns Hopkins University